The Trump administration has decided not to impose tariffs on generic drugs, narrowing the scope of its ongoing pharmaceutical trade investigation.
The Wall Street Journal carry the report. More:
Officials confirmed that the White House is no longer actively considering Section 232 tariffs on generic pharmaceuticals under the national-security probe initiated earlier this year. The decision follows internal debate over whether to use tariffs to bring drug manufacturing back to the U.S.
President Trump had previously threatened 100% tariffs on name-brand drugs, though he later delayed implementation to allow for negotiations with pharmaceutical companies. Generics—accounting for roughly 90% of all U.S. prescriptions—will be exempt for now, according to White House and Commerce Department spokespeople.
The move marks a major scaling-back of the Commerce Department’s initial investigation, which had targeted both generic and non-generic medicines as well as drug ingredients. It also reverses an earlier campaign pledge to restore production of essential generic drugs to the United States.
